1. Cytomegalovirus and Glioblastoma: A Review of the Biological Associations and Therapeutic Strategies
   Tianrui Yang et al, 2022, Journal of Clinical Medicine CrossRef
2. US28: HCMV’s Swiss Army Knife
   Benjamin Krishna et al, 2018, Viruses CrossRef
3. New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection
   Jan Korbecki et al, 2018, Oncotarget CrossRef
4. The role of CMV in glioblastoma and implications for immunotherapeutic strategies
   Maryam Rahman et al, 2019, OncoImmunology CrossRef
5. Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
   Mattia Russel Pantalone et al, 2022, Cancers CrossRef
6. The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth
   Raimond Heukers et al, 2018, Oncogene CrossRef
7. The impact of inflationary cytomegalovirus‐specific memory T cells on anti‐tumour immune responses in patients with cancer
   Xiao‐Hua Luo et al, 2018, Immunology CrossRef
8. Repurposing drugs for glioblastoma: From bench to bedside
   João Basso et al, 2018, Cancer Letters CrossRef
9. The human cytomegalovirus-encoded G protein–coupled receptor UL33 exhibits oncomodulatory properties
   Jeffrey R. van Senten et al, 2019, Journal of Biological Chemistry CrossRef
10. Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma
    Yu-Kai Huang et al, 2020, Medicine CrossRef
11. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
    Minjie Fu et al, 2023, BMC Cancer CrossRef
12. The Viral Connection to Glioblastoma
    J. Ricardo McFaline-Figueroa et al, 2017, Current Infectious Disease Reports CrossRef
13. Glioblastoma as a Novel Drug Repositioning Target: Updated State
    Hamed Hosseinalizadeh et al, 2023, Anti-Cancer Agents in Medicinal Chemistry CrossRef